HeraMED Overview
HeraMED is a technology start-up company developing connected pregnancy monitoring solutions for home use. HeraMEDs hardware solutions and software applications are focused on fetal well-being and parental assurance. The companys HeraBEAT is a medically accurate and scientifically optimized smartphone-based fetal heartbeat monitor for home use. HeraBEAT allows expectant mothers to monitor the fetal heartbeat anytime, anywhere and enables the seamless sharing of fetal vital sign data with medical professionals. HeraBEAT integrates technology and professional accuracy with a simple and straightforward user interface and a distinctive design, resulting in a safe, reliable, and affordable solution. HeraBEAT is BSI certified with the CE mark for medical devices. It received 510(k) clearance from the FDA in November 2019. The companys HeraCARE is a digital platform enabling a new model of care for women throughout pregnancy. HeraMEDs future products include the EchoBEAT line of home-based pregnancy monitoring devices and ORION, an AI-powered pregnancy monitoring system. Developed in cooperation with the Mayo Clinic, Orion is trained to detect precursors that can indicate possible pregnancy complications before they become a problem.
Cumulative Funding Raised Over Time ($)
$922KDec 2019
$2.4MFeb 2021
$2.5MJul 2020
$3.1MMar 2018
$6.1MNov 2015
$7.6MNov 2018
$9.7MNov 2024
Latest News
growth-negative
HeraMED First Half 2025 Earnings: AU$0.003 loss per share (vs AU$0.009 loss in 1H 2024)
HeraMED reported a revenue of AU$139.5k, which is down by 23% from the first half of 2024. The company also reported a net loss of AU$2.26 million, although this loss has narrowed by 30% compared to the same period last year. The loss per share has improved from AU$0.009 to AU$0.003. Despite these financial challenges, HeraMED shares have increased by 10% over the past week. The article also mentions that there are five warning signs for HeraMED, four of which are significant. The analysis provided is based on historical data and analyst forecasts, and it is not intended as financial advice.
growth-negative
HeraMED Full Year 2024 Earnings: AU$1.03 loss per share (vs AU$0.025 loss in FY 2023)
HeraMED reported a revenue of AU$364.3k, which is a 38% decrease from FY 2023. The company also reported a net loss of AU$5.49m, which is a 17% improvement from the previous fiscal year. The loss per share stands at AU$1.03. HeraMEDs shares have declined by 15% over the past week. The article highlights that there are six warning signs associated with HeraMED, five of which are concerning. The analysis provided is based on historical data and analyst forecasts and does not constitute financial advice.
growth-positive
Leading scientific publication backs HeraMED's foetal heartbeat monitor - Stockhead
The official publication of the American College of Obstetricians and Gynecologists has endorsed HeraMEDs foetal monitoring device. The endorsement is expected to increase awareness of the HeraCARE platform and HeraBEAT device, leading to new partnership opportunities. HeraMED is currently collaborating with Mayo Clinic and Sheba Medical Centre. The article highlights the accuracy and ease of use of the HeraBEAT device, positioning it as a viable alternative for medical professionals in pre-natal care.
Partners
growth-positive
Israel's largest hospital to pilot HeraMED (ASX:HMD) pregnancy tech
HeraMED will have its pregnancy monitoring solutions tested in a pilot study at Israels largest hospital, the Sheba Medical Centre. The pilot study will be conducted in multiple stages, with the first stage focusing on using the HeraBEAT smart pregnancy monitor in the dedicated pregnancy COVID-19 unit. The second stage will explore additional uses beyond COVID-19, such as high-risk pregnancies. HeraMED CEO is excited to partner with Sheba and looks forward to potential commercial partnership. The Director of the Sheba Womens Health Innovation Centre is also enthusiastic about the partnership and aims to provide premium maternal care using cutting-edge technologies.
Customers
growth-positive
HeraMED partners with Teleperinatal to launch HeraCARE and HeraBEAT - TechInvest Magazine Online
HeraMED Limited has signed a Letter of Intent with Teleperinatal to deploy its maternal care app and smart foetal HR monitor. The initial pilot will be followed by a formal commercial agreement. Teleperinatal provides a maternity benefits program for employers, and the partnership aims to reduce the cost of pregnancy care. The program will be sold directly to employers, with a focus on Fortune 500 Companies. Several contracts have already been secured, and it is estimated that over 10,000 pregnant women will be under management by the end of 2021. The partnership will involve the deployment of the HeraCARE mobile app and the sale of the HeraBEAT device. Teleperinatal will pay a license fee for the HeraCARE platform and offer the HeraBEAT device to its users for an additional fee. The partnership is part of HeraMEDs US market entry strategy.
PartnersCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $20.32M |
| Last funding | $2.11M |
| Stage | Public |
| Rounds | 12 |
| Investors | 4 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | www.hera-med.com |
Locations
Meir Ariel Street 6, Netanya, Israel
23-25 Hunter Street, Sydney NSW, Australia
Photos & Videos
4 item(s)
HeraMED Business
Business models
B2C, B2B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsDigital HealthcarePatient Remote MonitoringTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsConsumersDemographics & FamilyParentsWomenCore Technology
SensingCommunicationsIOTPlatforms & InterfacesMobileSoftwareArtificial IntelligenceMachine LearningTags (25)
femtechsensorspregnancyiotmhealthpatent-pendingdigital-healthcarehome-caremonitoringgynecologyemrwomen-healthmedical-dataactionable-insightsmobile-applicationsdata-analyticsmedical-devicesbig-dataremote-monitoringsoftware-applicationssaashealthcare-providershardwaremachine-learningartificial-intelligenceGeographic Markets
IndiaGlobalBrazilUnited KingdomIsraelTurkeyUnited StatesGermanyAustraliaMexicoEuropeChinaHeraMED Financials
$20.32M
Total funding
Undisclosed
Capital raised
$2.11M
Last funding
Public
Funding stage
12
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$922KDec 2019
$2.4MFeb 2021
$2.5MJul 2020
$3.1MMar 2018
$6.1MNov 2015
$7.6MNov 2018
$9.7MNov 2024
Private Equity Funding
PIPE
Nov 2024
$2.11M
PIPE
Feb 2021
$1.5M
Undisclosed Investor(s)
PIPE
Jul 2020
$100K
Mayo Clinic
PIPE
Dec 2019
$922K
Undisclosed Investor(s)
Convertible Debt
Nov 2018
$1.5M
Undisclosed Investor(s)
Equity crowdfunding
Mar 2018
$560.5K
ExitValley
Undisclosed Round
Nov 2015
$3M
Hofon Pharmaceuticals Co Ltd
Non-Equity Funding
GrantEvent
Jan 2016
$556K
Israel Innovation Authority
GrantEvent
Jan 2014
$1.15M
Israel Innovation Authority
GrantEvent
Jan 2012
$625K
Israel Innovation Authority
Public Offering / Exit
POEvent
Jun 2020
Undisclosed
POEvent
Dec 2018
Undisclosed
HeraMED Lifecycle
Cumulative Funding Raised Over Time
$922KDec 2019
$2.4MFeb 2021
$2.5MJul 2020
$3.1MMar 2018
$6.1MNov 2015
$7.6MNov 2018
$9.7MNov 2024
All Events
PIPE
Nov 2024
$2.11M
PIPE
Feb 2021
$1.5M
Undisclosed Investor(s)
PIPE
Jul 2020
$100K
Mayo Clinic
PIPE
Dec 2019
$922K
Undisclosed Investor(s)
Convertible Debt
Nov 2018
$1.5M
Undisclosed Investor(s)
Equity crowdfunding
Mar 2018
$560.5K
ExitValley
Undisclosed Round
Nov 2015
$3M
Hofon Pharmaceuticals Co Ltd
GrantEvent
Jan 2016
$556K
Israel Innovation Authority
GrantEvent
Jan 2014
$1.15M
Israel Innovation Authority
GrantEvent
Jan 2012
$625K
Israel Innovation Authority
POEvent
Jun 2020
Undisclosed
POEvent
Dec 2018
Undisclosed
HeraMED News
21 articles
growth-negative
HeraMED First Half 2025 Earnings: AU$0.003 loss per share (vs AU$0.009 loss in 1H 2024)
HeraMED reported a revenue of AU$139.5k, which is down by 23% from the first half of 2024. The company also reported a net loss of AU$2.26 million, although this loss has narrowed by 30% compared to the same period last year. The loss per share has improved from AU$0.009 to AU$0.003. Despite these financial challenges, HeraMED shares have increased by 10% over the past week. The article also mentions that there are five warning signs for HeraMED, four of which are significant. The analysis provided is based on historical data and analyst forecasts, and it is not intended as financial advice.
growth-negative
HeraMED Full Year 2024 Earnings: AU$1.03 loss per share (vs AU$0.025 loss in FY 2023)
HeraMED reported a revenue of AU$364.3k, which is a 38% decrease from FY 2023. The company also reported a net loss of AU$5.49m, which is a 17% improvement from the previous fiscal year. The loss per share stands at AU$1.03. HeraMEDs shares have declined by 15% over the past week. The article highlights that there are six warning signs associated with HeraMED, five of which are concerning. The analysis provided is based on historical data and analyst forecasts and does not constitute financial advice.
growth-positive
Leading scientific publication backs HeraMED's foetal heartbeat monitor - Stockhead
The official publication of the American College of Obstetricians and Gynecologists has endorsed HeraMEDs foetal monitoring device. The endorsement is expected to increase awareness of the HeraCARE platform and HeraBEAT device, leading to new partnership opportunities. HeraMED is currently collaborating with Mayo Clinic and Sheba Medical Centre. The article highlights the accuracy and ease of use of the HeraBEAT device, positioning it as a viable alternative for medical professionals in pre-natal care.
Partners
growth-positive
Israel's largest hospital to pilot HeraMED (ASX:HMD) pregnancy tech
HeraMED will have its pregnancy monitoring solutions tested in a pilot study at Israels largest hospital, the Sheba Medical Centre. The pilot study will be conducted in multiple stages, with the first stage focusing on using the HeraBEAT smart pregnancy monitor in the dedicated pregnancy COVID-19 unit. The second stage will explore additional uses beyond COVID-19, such as high-risk pregnancies. HeraMED CEO is excited to partner with Sheba and looks forward to potential commercial partnership. The Director of the Sheba Womens Health Innovation Centre is also enthusiastic about the partnership and aims to provide premium maternal care using cutting-edge technologies.
Customers
growth-positive
HeraMED partners with Teleperinatal to launch HeraCARE and HeraBEAT - TechInvest Magazine Online
HeraMED Limited has signed a Letter of Intent with Teleperinatal to deploy its maternal care app and smart foetal HR monitor. The initial pilot will be followed by a formal commercial agreement. Teleperinatal provides a maternity benefits program for employers, and the partnership aims to reduce the cost of pregnancy care. The program will be sold directly to employers, with a focus on Fortune 500 Companies. Several contracts have already been secured, and it is estimated that over 10,000 pregnant women will be under management by the end of 2021. The partnership will involve the deployment of the HeraCARE mobile app and the sale of the HeraBEAT device. Teleperinatal will pay a license fee for the HeraCARE platform and offer the HeraBEAT device to its users for an additional fee. The partnership is part of HeraMEDs US market entry strategy.
PartnersCustomers
growth-positive
Mayo Clinic approves clinical study of HeraMED's HeraBEAT device - Stockhead
Mayo Clinic has approved HeraMEDs HeraBEAT device for a clinical study to begin in December 2020. The study will be conducted at the Department of Obstetrics and Gynaecology at Mayo Clinic in Rochester, Minnesota and will recruit 50 low-risk expectant mothers. This approval marks an important step in HeraMEDs commercialization strategy and aligns the company with leading healthcare providers and medical institutions. The trial will assess the functionality and user acceptability of HeraMEDs services and evaluate the impact of the device on the perception of fetal wellbeing. This is the second clinical trial for HeraBEAT, following successful results in Western Australia.
Partners
growth-positive
HeraMED taps into US healthcare market with eCare21 partnership - Stockhead
HeraMED, a medical tech company providing in-home maternity care, has partnered with US-based virtual care platform eCare21 to expand its services in the US. The partnership will allow HeraMED to integrate its services with eCare21s digital technology platform. The integration is expected to be completed in the coming weeks, enabling HeraMED to market to an established pipeline of potential customers. The companys mother and baby heart monitoring device, HeraBEAT, and its HeraCARE health services platform will be included in the eCare21 platform.
PartnersExpand
growth-positive
HeraMed and US-based eCare21 reach partnership agreement - TechInvest Magazine Online
HeraMED Limited has signed a Letter of Intent with eCare21 to integrate its technology into the eCare21 platform. The collaboration aims to strengthen eCare21s virtual care platform with a maternal health monitoring solution. HeraMEDs HeraCARE platform, including its in-home foetal and maternal heart rate monitor HeraBEAT, will be fully integrated into the eCare21 platform. The integrated solution is expected to simplify the deployment of virtual care for maternal health patients and providers. The partnership provides HeraMED with access to a large number of healthcare providers experienced in remote monitoring services. The company is well-positioned to deliver high-quality prenatal and postpartum care and capitalize on opportunities in the digital health market.
Partners
growth-positive
HeraMED announces new research collaboration with Mayo Clinic - Stockhead
Healthtech company HeraMED has extended its collaboration with Mayo Clinic medical research centre for the development of its pre-natal health platform, HeraCARE. Mayo Clinic will contribute to fund research initiatives and provide a license to its library of educational content, and expert medical know-how and guidelines in the field of prenatal care. The collaboration will allow patients using the HeraMED platform access to Mayo’s library of educational content while Mayo’s clinicians study the implementation of its HeraCARE platform. HeraMED recently raised $2.3m in capital and is running clinical trials in Australia for its remote monitoring technology.
PartnersInvestment
growth-positive
HeraMED (ASX:HMD) signs agreement to initiate pilot program
HeraMED has signed agreements with Freeman Road and the PHI group to begin pilot programs in Australia for its telehealth pregnancy care apps. The partnership aims to advance clinical studies and streamline pregnancy care. Freeman Road will lead the studies and receive options from HeraMED as it hits certain milestones. The pilot program will be conducted at the Joondalup Health Campus in Perth, examining the usability and acceptability of the HeraBEAT device. HeraMED hopes to leverage the partnership to expand its technology globally. The CEO of HeraMED, David Groberman, expressed pride in the deal and the collaboration with prominent leaders in the Australian medical community.
Partners
HeraMED appoints US General Manager of Operations - HeraMED Limited (ASX:HMD)
HeraMED (ASX:HMD) reveals $1.42M raising for U.S. market
HeraMED CEO David Groberman talks about the company's progress
growth-positive
HeraMED's distributor in India secures new deal for HeraBEAT
HeraMEDs distributor in India has secured a service partnership with Cloudnine Hospital Group. Cloudnine customers will be able to rent HeraMEDs HeraBEAT foetal heart rate monitors. The partnership allows expectant mothers to monitor their foetus heartbeat anytime, anywhere. The distributor, Consultus India, will sell the devices under their H-Cube brand. HeraMEDs market entry into India is showing positive progress, providing a gold standard alternative to more expensive competitor products.
Partners
HeraMED adds telehealth services to Herabeat in Germany
growth-positive
HeraMED receives FDA clearance for HeraBEAT
Medical technology company HeraMED Limited has received FDA clearance for its HeraBEAT US foetal ultrasonic heart rate monitor. The clearance allows the product to be commercially distributed throughout the United States, marking a significant milestone for the company. HeraMED already has established relationships with the Mayo Clinic and other medical institutions, which will help drive growth and product uptake in the US market. The HeraBEAT US device is a portable ultrasound Doppler device that enables personalised, continuous, and proactive home monitoring for expecting mothers. The company aims to deliver better care at a lower cost and enable early detection of potential risks.
CustomersPartners
growth-positive
HeraMED Transforming the Prenatal Care Via End-to-End Medical Grade Solutions
The article discusses the range of retail stocks offered by the Australian Securities Exchange (ASX) and evaluates them as potential bargains or pitfalls. The ASX is experiencing growth in its retail stocks, which is positive for the company. The key theme of the article is the evaluation of retail stocks on the ASX. The key issues discussed are customers and partners. The article does not mention any specific customers or partners. The date of the event described in the article is not provided. The confidence level of the answer is 7.
CustomersPartners
growth-positive
Israeli dad invents fetal heart rate monitor for home use
HeraMED, a med-tech startup, has developed HeraBEAT, a smartphone-based fetal heartbeat monitor for home use. The device allows expectant mothers to monitor their fetus heartbeat and securely share the data with healthcare providers. HeraMED completed its IPO on the Australian Securities Exchange and has received regulatory approvals in multiple countries. The Mayo Clinic is testing HeraBEAT as part of its OB Nest program. The company aims to revolutionize pregnancy care by offering home-based, continuous monitoring. HeraMED is also developing a new product called Orion, which uses artificial intelligence to analyze medical records and identify risk factors for complications.
CustomersInvestmentPublic Trading
growth-positive
HeraMED's pregnancy monitors just won over one of Brazil's biggest healthcare providers - Stockhead
HeraMED, a pregnancy monitoring company, has signed a deal with major healthcare provider Hapvida to use its pregnancy monitoring devices and software services. The deal was signed a year earlier than expected and allows up to 100 pregnant Brazilian women to use HeraMEDs smart ultrasound fetal heart rate monitors. HeraMED aims to become the market leader in real-time pregnancy data and generate revenue through subscription fees and device sales. The company plans to expand its services to Europe, the US, and Australia. The deal with Hapvida is part of a pilot scheme, and once proven successful, HeraMED hopes to partner with other hospitals.
Customers
HeraMED raises NIS 16m in Australian IPO
http://www.geektime.com/2016/09/14/this-israeli-startups-home-ultrasound-makes-sonoline-b-look-like-a-toy/
HeraMED Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 19 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 21 classification IDs that could be used for matching.
HeraMED Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514676543 |
| Crunchbase | heramed |
| Phone | +97298803010 |
| Last updater | Yotam Maman |
| Updater email | yotamm1988@gmail.com |
| Last update | 2021-03-22T00:00:00.000Z |
| Created | 2014-07-29T00:00:00.000Z |
| Status detail | Public on ASX on Dec, 2018<br> |